{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:20Z","timestamp":1790668520919,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01275-2","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:29:06Z","timestamp":1788974946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity Assays Used in Support of Marketing Applications of Oligonucleotide Therapeutics"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9193-5845","authenticated-orcid":false,"given":"Cecilia","family":"Arfvidsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3696-3119","authenticated-orcid":false,"given":"Lin-Zhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1407-8687","authenticated-orcid":false,"given":"Susovan","family":"Mohapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0372-830X","authenticated-orcid":false,"given":"Kamalika","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6573-3024","authenticated-orcid":false,"given":"Pallab","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7020-8445","authenticated-orcid":false,"given":"Gnana Oli","family":"Rajaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9432-3956","authenticated-orcid":false,"given":"Arkadeep","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9966-2129","authenticated-orcid":false,"given":"Christopher C.","family":"Stebbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7983-4860","authenticated-orcid":false,"given":"Zhandong Don","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2953-1131","authenticated-orcid":false,"given":"Robert J.","family":"Kubiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"1275_CR1","unstructured":"US Food and Drug Administration (2024). Guidance for Industry: Clinical pharmacology consideration for the development of oligonucleotide therapeutics.\u00a0https:\/\/www.fda.gov\/media\/159414\/download"},{"key":"1275_CR2","doi-asserted-by":"crossref","unstructured":"Egli M, Manoharan M (2023). Chemistry, structure and function of approved oligonucleotide therapeutic. Nucleic Acids Research, 2023; 51(6):2529\u20132573.","DOI":"10.1093\/nar\/gkad067"},{"key":"1275_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/21593337251387423","author":"J Grudzinska-Goebel","year":"2025","unstructured":"Grudzinska-Goebel J, Braun M, Chen LZ, Gupta S, Lohmann S, Morais P, et al. Immunogenicity risk assessment for nucleic acid therapeutics: a comprehensive evaluation for ASO, siRNA, and nonvaccine mRNA\/LNP therapies by the IQ consortium. Nucleic Acid Ther. 2025. https:\/\/doi.org\/10.1177\/21593337251387423.","journal-title":"Nucleic Acid Ther"},{"key":"1275_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1208\/s12248-025-01023-y","volume":"27","author":"BW Pack","year":"2025","unstructured":"Pack BW, Siegel RW, Cornwell PD, Ferrante A, Roepke DA, Hodson ME, et al. A Phase -Appropriate Risk Assessment Strategy in Support of the Safety of Peptide and Oligonucleotide-Related Impurities. AAPS J. 2025;27:56.","journal-title":"AAPS J"},{"key":"1275_CR5","unstructured":"US Food and Drug Administration (2014). Guidance for industry: immunogenicity assessment for therapeutic protein products.\u00a0https:\/\/www.fda.gov\/media\/85017\/download"},{"key":"1275_CR6","unstructured":"US Food and Drug Administration (2019). Immunogenicity testing of therapeutic protein products \u2014 developing and validating assays for anti-drug antibody detection.\u00a0https:\/\/www.fda.gov\/media\/119788\/download"},{"issue":"21","key":"1275_CR7","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.4155\/bio-2019-0133","volume":"11","author":"CCS Stebbins","year":"2014","unstructured":"Stebbins CCS, Petrillo M, Stevenson L. Immunogenicity for antisense oligonucleotides: a risk-based assessment. Bioanalysis. 2014;11(21):1913\u20136.","journal-title":"Bioanalysis"},{"key":"1275_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1208\/s12248-022-00741-x","volume":"24","author":"N Bano","year":"2022","unstructured":"Bano N, Ehlinger C, Yanf T-Y, Swanson M, Allen S. Considerations in the immunogenicity assessment strategy for oligonucleotide therapeutics (ONTs). AAPS J. 2022;24:93.","journal-title":"AAPS J"},{"issue":"5","key":"1275_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/nat.2021.0112","volume":"32","author":"SP Henry","year":"2022","unstructured":"Henry SP, Arfvidsson C, Arrington J, Canadi J, Crowe D, Gupta S, et al. Assessment of the immunogenicity potential for oligonucleotide-based drugs. Nucleic Acid Ther. 2022;32(5):369\u201377.","journal-title":"Nucleic Acid Ther"},{"key":"1275_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","volume":"289","author":"AR Mire-Sluis","year":"2004","unstructured":"Mire-Sluis AR, Barret YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289:1\u201316.","journal-title":"J Immunol Methods"},{"key":"1275_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jpba.2013.06.005","volume":"86","author":"Y Wu","year":"2013","unstructured":"Wu Y, Liu X, Chen Y, et al. An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype. J Pharm Biomed Anal. 2013;86:73\u201381.","journal-title":"J Pharm Biomed Anal"},{"issue":"1\u20132","key":"1275_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jim.2013.07.010","volume":"396","author":"DK Weeraratne","year":"2013","unstructured":"Weeraratne DK, Lofgren J, Dinnogen S, Swanson SJ, Zhong ZD. Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference. J Immunol Methods. 2013;396(1\u20132):44\u201355.","journal-title":"J Immunol Methods"},{"issue":"2","key":"1275_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1208\/s12248-020-0413-z","volume":"22","author":"LL Jiang","year":"2020","unstructured":"Jiang LL, Khandelwal P, Clarke AW, Bakhtiar R, Zou L, Zhong ZD. Development and Utility of an ELISA Method for Sensitive and Specific Detection of IgE Antidrug Antibodies. AAPS J. 2020;22(2):36.","journal-title":"AAPS J"},{"key":"1275_CR14","unstructured":"Viltolarsen (VILTEPSO\u00ae). Application 212154Orig1s000 Other Review(s) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/212154Orig1s000OtherR.pdf"},{"key":"1275_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1090237","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang L, Liang Y, Tian Z, Zhang Y, Liu Z, Ji X. The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates. Front Pharmacol. 2022;13:1090237.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1275_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/jcph.2337","volume":"64","author":"G An","year":"2023","unstructured":"An G. Pharmacokinetics and pharmacodynamics of GalNAc-conjugated siRNAs. J Clin Pharmacol. 2023;64(1):45\u201357.","journal-title":"J Clin Pharmacol"},{"key":"1275_CR17","unstructured":"Olezarsen (TRYNGOLZA\u2122). Integrated Review https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/218614Orig1s000IntegratedR.pdf"},{"key":"1275_CR18","unstructured":"Donidalorsen (DAWNZERA\u2122). Application 217388Orig1s000 Other Review(s) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/219407Orig1s000OtherR.pdf"},{"issue":"8","key":"1275_CR19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4155\/bio.14.56","volume":"6","author":"B Gorovits","year":"2014","unstructured":"Gorovits B, McNally J, Fiorotti C, Leung S. Protein-based matrix interferences in ligand-binding assays. Bioanalysis. 2014;6(8):1131\u201340.","journal-title":"Bioanalysis"},{"issue":"6","key":"1275_CR20","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1208\/s12248-017-0148-7","volume":"19","author":"ZD Zhong","year":"2017","unstructured":"Zhong ZD, Clemens-Egan A, Gorovits B, Maia M, Sumner G, Theobald V, et al. Drug target interference in immunogenicity assays: recommendations and mitigation strategies. AAPS J. 2017;19(6):1564\u201375.","journal-title":"AAPS J"},{"issue":"12","key":"1275_CR21","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.4155\/bio.10.136","volume":"2","author":"AM Butterfield","year":"2010","unstructured":"Butterfield AM, Chain JS, Ackerman BL, Konrad RJ. Comparison of assay formats for drug-tolerant immunogenicity testing. Bioanalysis. 2010;2(12):1961\u20139.","journal-title":"Bioanalysis"},{"key":"1275_CR22","unstructured":"Defibrotide (DEFITELIO\u00ae). Application 208114Orig1s000 Summary Review https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208114Orig1s000SumR.pdf"},{"key":"1275_CR23","unstructured":"Eteplirsen (EXONDYS 51\u00ae). NDA 206488 Accelerated Approval Letter https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2016\/206488orig1s000ltr.pdf"},{"key":"1275_CR24","unstructured":"Golodirsen (Vyondys 53). Application 211970Orig1s000 Summary Review https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211970Orig1s000SumR.pdf"},{"key":"1275_CR25","unstructured":"Casimersen (AMONDYS 45\u00ae). Application 213026Orig1s000 Other Review(s) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/213026Orig1s000OtherR.pdf"},{"key":"1275_CR26","unstructured":"Inclisiran (LEQVIO\u00ae). Application 214012Orig1s000 Summary Review https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214012Orig1s000SumR.pdf"},{"key":"1275_CR27","unstructured":"US Food and Drug Administration (2009). Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins, US Food and Drug Administration. 2009; Rockville, MD."},{"key":"1275_CR28","unstructured":"Fomivirsen (VITRAVENE\u00ae). Application No.: 20\u2013961 Clinical Pharmacology\/Biopharmacutical Review https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/98\/20961_Vitravene_biopharmr.pdf"},{"key":"1275_CR29","unstructured":"Pegaptanib (MACUGEN\u00ae). Application 021756 Clinical Pharmacology\/Biopharmacutical Review https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/21-756_Macugen_biopharmr.pdf"},{"key":"1275_CR30","unstructured":"Avacincaptad pegol (IZERVEY\u2122). Application 217225Orig1s000 Clinical Review(s) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/217225Orig1s000MedR.pdf"},{"issue":"2","key":"1275_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0022-1759(84)90469-1","volume":"67","author":"H Borel","year":"1984","unstructured":"Borel H, Sasaki T, Stollar DB, Borel Y. Conjugation of DNA fragments to protein carriers by glutaraldehyde: immunogenicity of oligonucleotide-hemocyanin conjugates. J Immunol Methods. 1984;67(2):289\u2013302.","journal-title":"J Immunol Methods"},{"issue":"1","key":"1275_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ymthe.2016.10.001","volume":"25","author":"K Kramer","year":"2017","unstructured":"Kramer K, Shields NJ, Poppe V, Young SL, Walker GF. Intracellular cleavable CpG oligodeoxynucleotide-antigen conjugate enhances anti-tumor immunity. Mol Ther. 2017;25(1):62\u201370.","journal-title":"Mol Ther"},{"issue":"1","key":"1275_CR33","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1038\/s41598-021-85709-1","volume":"11","author":"AM Weiss","year":"2021","unstructured":"Weiss AM, Ajit J, Albin TJ, Kapoor N, Maroju S, Berges A, et al. Site-specific antigen-adjuvant conjugation using cell-free protein synthesis enhances antigen presentation and CD8+ T-cell response. Sci Rep. 2021;11(1):6267.","journal-title":"Sci Rep"},{"key":"1275_CR34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.immuni.2016.04.002","volume":"44","author":"A Roers","year":"2016","unstructured":"Roers A, Hiller B, Hornung V. Recognition of endogenous nucleic acids by the innate immune system. Immunity. 2016;44:739\u201354.","journal-title":"Immunity"},{"issue":"1","key":"1275_CR35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/nat.2024.0065","volume":"35","author":"DP Chimento","year":"2025","unstructured":"Chimento DP, Anderson AL, Fial I, Ascoli CA. Bioanalytical assays for oligonucleotide therapeutics: adding antibody-based immunoassays to the toolbox as an orthogonal approach to LC-MS\/MS and ligand binding assays. Nucleic Acid Ther. 2025;35(1):6\u201315.","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"1275_CR36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1177\/21593337251361396","volume":"35","author":"I Fial","year":"2025","unstructured":"Fial I, Farrier SA, Chimento DP, Ascoli CA, Wan X, Oliver PL. Characterizing Antibodies Targeting Antisense Oligonucleotide Phosphorothioate and 2\u2019-O-Methoxyethyl Modification for Intracellular Trafficking and Biodistribution Studies. Nucleic Acid Ther. 2025;35(4):168\u201381.","journal-title":"Nucleic Acid Ther"},{"key":"1275_CR37","unstructured":"Mipomersen (KYNAMRO\u00ae). FDA Application 203568Orig1s000 Other Review(s) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/203568Orig1s000OtherR.pdf"},{"key":"1275_CR38","unstructured":"Eteplirsen (EXONDYS 51\u00ae). NDA 206488 Summary Review https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206488_summary%20review_redacted.pdf"},{"key":"1275_CR39","unstructured":"Nusinersen (SPINRAZA\u00ae). FDA Application 209531Orig1s000 Other Review(s) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/209531Orig1s000OtherR.pdf"},{"key":"1275_CR40","unstructured":"Nusinersen (SPINRAZA\u00ae). Highlights of prescribing information. April 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/209531s013s014lbl.pdf"},{"key":"1275_CR41","unstructured":"Patisiran (ONPATTRO\u00ae). Application 210922Orig1s000 Other Review(s) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210922Orig1s000OtherR.pdf"},{"key":"1275_CR42","unstructured":"Patisiran (ONPATTRO\u00ae). Highlights of prescribing information. January 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/210922s012lbl.pdf"},{"key":"1275_CR43","unstructured":"Inotersen (TEGSEDI\u00ae). Application 211172Orig1s000 Other review(s) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211172Orig1s000OtherR.pdf"},{"key":"1275_CR44","unstructured":"Volanesorsen (WAYLIVRA\u00ae). EMA Procedure No. EMEA\/H\/C\/004538\/0000 Assessment Report https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/waylivra-epar-public-assessment-report_en.pdf"},{"key":"1275_CR45","unstructured":"Volanesorsen (WAYLIVRA\u00ae). Summary of product characteristics. July 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/waylivra-epar-product-information_en.pdf"},{"key":"1275_CR46","unstructured":"Givosiran (GIVLAARI\u00ae). Application 212194Orig1s000 Multi-Discipline Review https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212194Orig1s000MultidisciplineR.pdf"},{"key":"1275_CR47","unstructured":"Givosiran (GIVLAARI\u00ae). Highlights of prescribing information. April 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/212194s007lbl.pdf"},{"key":"1275_CR48","unstructured":"Viltolarsen (VILTEPSO\u00ae). Highlights of prescribing information. March 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212154s002lbl.pdf"},{"key":"1275_CR49","unstructured":"Lumasiran (OXLUMO\u00ae). Application 214103Orig1s000, Integrated review https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/214103Orig1s000IntegratedR.pdf"},{"key":"1275_CR50","unstructured":"Lumasiran (OXLUMO\u00ae). Highlights of prescribing information. April 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/214103s006lbl.pdf"},{"key":"1275_CR51","unstructured":"Inclisiran (LEQVIO\u00ae). Highlights of prescribing information. July 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/214012s016lbl.pdf"},{"key":"1275_CR52","unstructured":"Vutrisiran (AMVUTTRA\u00ae). EMA Procedure No. EMEA\/H\/C\/005852\/0000 Assessment Report https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/amvuttra-epar-public-assessment-report_en.pdf"},{"key":"1275_CR53","unstructured":"Vutrisiran (AMVUTTRA\u00ae). Highlights of prescribing information. March 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215515s006lbl.pdf"},{"key":"1275_CR54","unstructured":"Tofersen (QALSODY\u00ae). Application 215887Orig1s000 Other Review(s) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/215887Orig1s000OtherR.pdf"},{"key":"1275_CR55","unstructured":"Tofersen (QALSODY\u00ae). Highlights of prescribing information. April 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215887Orig1s000Correctedlbl.pdf"},{"key":"1275_CR56","unstructured":"Nedosiran (RIVFLOZA\u2122). Application 215842Orig1s000 Integrated Review https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/215842Orig1s000IntegratedR.pdf"},{"key":"1275_CR57","unstructured":"Nedosiran (RIVFLOZA\u2122). Highlights of prescribing information. March 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215842s002lbl.pdf"},{"key":"1275_CR58","unstructured":"Eplontersen (WEINUA\u2122). Application 217388Orig1s000 Other Review(s) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217388Orig1s000OtherR.pdf"},{"key":"1275_CR59","unstructured":"Eplontersen. (WEINUA\u2122). Highlights of prescribing information. April 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217388Orig1s004lbl.pdf"},{"key":"1275_CR60","unstructured":"Olezarsen (TRYNGOLZA\u2122). Highlights of prescribing information. December 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218614s000lbl.pdf"},{"key":"1275_CR61","unstructured":"Fitusiran (QFITLIA\u2122). Highlights of prescribing information. March 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219019s000lbl.pdf"},{"key":"1275_CR62","unstructured":"Donidalorsen (DAWNZERA\u2122). Highlights of prescribing information. August 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219407s000lbl.pdf"},{"key":"1275_CR63","unstructured":"Plozasiran (REDEMPLO\u00ae). Highlights of prescribing information. November 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219947s000lbl.pdf"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01275-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:03:10Z","timestamp":1790665390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01275-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":63,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1275"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01275-2","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are employed by and receive compensation from their affiliations that are listed in this manuscript. The authors have no other relevant affiliations or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"139"}}